Calquence approved in Japan to treat chronic lymphocytic leukaemia

eAwaz Medicine

Calquence significantly increased the time patients lived without disease progression or death vs. chemoimmunotherapy   UK – AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL. The …

astra zeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

eAwaz Medicine

Acquisition to access global rights to baxdrostat, a novel aldosterone synthase inhibitor in development for blood pressure lowering UK – AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition will bolster AstraZeneca’s cardiorenal …

AstraZeneca vaccine 1 1

AstraZeneca’s Covid vax linked to 30% higher risk to get rare blood clotting

eAwaz Medicine

London (AFP) – A new study, published in the journal BMJ, was the first to compare thrombocytopenia rates between adenovirus and mRNA vaccines — such as Pfizer — across multiple countries. It has found that AstraZeneca’s Covid vaccine is linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab. Several countries …

AstraZenecas Forxiga

Forxiga approved in China for the treatment of chronic kidney disease

eAwaz Medicine

London – AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D). The approval by China’s …

Farxiga dapagliflozin

New data show Farxiga significantly lowers risk of cardiovascular deaths

eAwaz Medicine

London – New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga (dapagliflozin), compared to placebo, in patients with heart failure (HF). These results were presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain and simultaneously published in Nature Medicine1. The reduction in risk of cardiovascular (CV) …


Lynparza granted Priority Review in US amid prostate cancer concerns

eAwaz Medicine

First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations London – AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate …


Enhertu delays disease progression in DESTINY-Breast02 Phase III trial

eAwaz Medicine

Ottawa – Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1). The trial also met the key secondary …


Tezspire recommended for approval in the EU

eAwaz Medicine

London – AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive …

Mixing vaccines

Current booster shots effective against Omicron

eAwaz Medicine

New York – Omicron sub-variants evades antibody responses from Covid vaccines but a new lab study suggests that the current booster doses can be effective. University of Washington researchers saw the functional impact of mutations in  Omicron sub-variants. They used Moderna, Pfizer, Novavax, Janssen, AstraZeneca, Sinopharm, and Sputnik V vaccines. All two-dose vaccines, except for Janssen’s single dose vaccine were …


Enhertu recommended for approval in the EU

eAwaz Medicine

London – AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and …